Furthermore, SGLT2 inhibitors impact kidney function by regulating cell migration, reducing oxidative stress, and mitigating the effects of high glucose levels on proximal tubule cells, showing potential as therapeutic agents for diabetic nephropathy. Here, SLC5A2 is linked to diabetic kidney disease.